Abstract:Triple-negative breast cancer (TNBC), with a lack of ERs, PRs, and HER2s as potential treatment targets, is insensitive to the hormonal and trastuzumab therapies and generally has a worse prognosis than other types of breast cancer. Thus, local and regional treatments such as radiotherapy are placed with more emphasis when treating patients with TNBC. By analyzing expression profiles of mRNAs, we provided a detailed landscape of the constituents of the tumor immune microenvironment to facilitate individualized treatment of patients with TNBC. Between January 1, 2010 and December 31, 2012, a total of 44 consecutive female patients diagnosed with a non-metastasized invasive TNBC who received adjuvant radiotherapy in our institution were identified in the present study. TNBC was defined as tumors with negative IHC for the ER (<1%), PR (<1%) and low or absent HER2-amplification (IHC 0 or 1+ or negative in situ hybridization). The Affymetrix Human Transcriptome Array 2.0 (HTA 2.0) GeneChips (Affymetrix) was used to determine the transcriptome profiles of 44 TNBC tissues samples. QRT-PCR was used to detected the expression of candidate RNAs. Gene set enrichment analysis (GSEA) was applied to investigate the functional associations of gene sets. CIBERSORT, a deconvolution algorithm enumerating infiltrating leucocytes, was performed to determine the relative fraction of 22 immune cell types in TNBC tumor tissues. Recurrence free survival (RFS) events included the following: the first recurrence of invasive disease at a local, regional, or distant site; contralateral breast cancer; and death from any cause. The median follow-up time was 51 months (range, 2.4–97.4 months). Fourteen patients (31.8%) developed disease recurrences. The 5-year accumulative RFS rate was 66.4%. By analyzing the transcriptome profiles of 14 patients with recurrence and 30 patients with no recurrence after radiotherapy, we observed that 281 mRNAs were up-regulated and 384 mRNAs were down-regulated in patients with recurrence, based on a p value cut-off of 0.05 and a greater than 1.2-fold change. GSEA revealed that gene sets related to immune responses are systematically down-regulated in patients with recurrence. We further determined the relative fraction of 22 immune cell types by using CIBERSORT. The most abundant cells were macrophages (39.4% of all leucocytes) with immunosuppressive M2 macrophages being the predominant population, followed by T cells (33.3% of all leucocytes). Increased M2 macrophages and resting mast cells were associated with high radiation resistance. In addition, we found that high expression of genes related to amino acid transportation correlated with inhibited immune responses and shorter RFS (p = 0.033). Our results suggested that immune response inhibition is significantly associated with radiation resistance in patients with TNBC with amino acid transportation might playing an important role.

Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB

Activation of ERβ Hijacks the Splicing Machinery to Trigger R-loop Formation in Triple-Negative Breast Cancer

Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.

Exploiting a Tumor Softening Targeted Bomb for Mechanical Gene Therapy of Chemoresistant Triple-Negative Breast Cancer

Β-Elemene Enhances Radiosensitivity in Non-Small-cell Lung Cancer by Inhibiting Epithelial–mesenchymal Transition and Cancer Stem Cell Traits Via Prx-1/NF-kB/iNOS Signaling Pathway

Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF

Abstract 3198: Comprehensive Transcriptome Analysis Identifies Integrated Mrna-Lncrna Signature of Triple-Negative Breast Cancer Treated with Radiotherapy

Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells

Radiation Enhances the Efficacy of EGFR-targeted CAR-T Cells Against Triple-Negative Breast Cancer by Activating NF-κB/Icam1 Signaling.

UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation

Transcriptome Profiling Reveals Novel Radiosensitivity Predictors by Integrating Molecular Subtype and Radiosensitivity Signature in Triple-Negative Breast Cancer

CXCR6 expression correlates with radiotherapy response and immune context in triple-negative breast cancer-experimental studies

Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy

RNA-binding protein p54nrb/NONO potentiates nuclear EGFR-mediated tumorigenesis of triple-negative breast cancer

BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer

Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation

Transcriptome Profiling Reveals Inhibited Immune Responses Associated with Radiation Resistance in Triple-Negative Breast Cancer

Inhibition of LNC EBLN3P Enhances Radiation-Induced Mitochondrial Damage in Lung Cancer Cells by Targeting the Keap1/Nrf2/HO-1 Axis.

Abstract 533: OTULIN promotes resistance and metastasis upon chemotherapy in TNBC by activating Wnt/β-Catenin signaling

FOS‐Mediated PLCB1 Induces Radioresistance and Weakens the Antitumor Effects of CD8+ T Cells in Triple‐Negative Breast Cancer

Building Radiation-Resistant Model in Triple-Negative Breast Cancer to Screen Radioresistance-Related Molecular Markers